Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Globe Newswire•06/10/2026•07:00 ET
0
Key Highlights
- ➤Regeneron will present 10 ESMO 2026 abstracts spanning five cancer-related areas
- ➤C-POST Phase 3 delivers approximately 3.5-year overall-survival data for adjuvant Libtayo in high-risk CSCC
- ➤Final Phase 2 analysis evaluates neoadjuvant Libtayo before surgery in stage II-IV CSCC
- ➤Factor XI programs cenvacibart and amrecibart advance with thrombosis data and ROXI-CAT-II update
- ➤Ubamatamab studies add ovarian and endometrial cancer data, including survival-associated biomarkers
Expert Statements
Israel Lowy, M.D., Ph.D., Clinical Development Unit Head, Oncology, at Regeneron
“At ESMO, we look forward to sharing data across a range of conditions reflecting the breadth of our research. For the first time, we’re showcasing how our work extends beyond the treatment of cancer itself, and addresses some of the complex challenges patients face as a result of their disease. Together, these data reflect our broader commitment to advancing comprehensive cancer care for patients.”
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo(®) (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation
Final Phase 2 analysis explores potential of Libtayo before surgery (neoadjuvant treatment) for patients with resectable CSCC
Get started
Create a free account to read the full story.